All Blogs
Sep 26, 2022
PDE4-B Inhibitors: A Promising Target for Idiopathic Pulmonary Fibrosis Treatment
Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve ...
Read More...
Jul 14, 2025
How Novel Therapies Could Transform the Ulcerative Colitis Treatment Landscape
Nearly two decades ago, treatment options for ulcerative colitis were limited, and selecting appropriate ulcerative colitis medications largely depended on disease severity and prior therapy response. Physicians often relied on combination approaches to optimize outcomes. Historically, the primary treatments for ul...
Read More...
Sep 22, 2022
Smith+Nephew’s OR3O Dual Mobility System; Medtronic Launches the Evolut FX Next-Gen TAVR System; FDA Approves Edwards’s Pascal Precision Transcatheter Valve Repair System; FDA Clearance to Zimmer Biomet’s Identity Shoulder System; Otsuka Announces Results of RADIANCE II Trial; Smith+Nephew Announces Data for its REGENETEN™ Bioinductive Implant
OR3O™ Dual Mobility System launched by Smith+Nephew in Japan for use in primary and revision hip arthroplasty On September 20, 2022, Smith+Nephew, a leading global portfolio medical technology business, announced the launch of OR3O Dual Mobility System for use in primary and revision hip arthro...
Read More...
Oct 06, 2025
Brain-Computer Interface (BCI) Applications Driving Healthcare Innovation
Brain-Computer Interfaces (BCIs) are emerging as a groundbreaking technology in the healthcare sector, offering innovative solutions for patients with neurological disorders, spinal cord injuries, and other debilitating conditions. A BCI is a direct communication pathway between the brain and external devices, enab...
Read More...
Sep 20, 2022
AstraZeneca’s Danicopan Trial; CHMP Recommends Sanofi/AstraZeneca’s nirsevimab; Akero’s NASH Drug Trial; FDA Grants Orphan Drug Status to SY-5609; BMS’s Opdivo Trial Results; Pfizer to File for FDA Approval for Meningitis Vaccine; EMA Orphan Drug Designation to CAN-2409; FDA Starts Priority Review of Chiesi ‘s velmanase alfa
AstraZeneca’s Danicopan Shows Positive Results in Phase III Trial Danicopan, an oral Factor D inhibitor developed by AstraZeneca, was expected to fail a phase II trial in rare kidney disease in 2020, but a new readout could revive the drug. Danicopan (ALXN2040) has demonstrated efficacy as an adjunct treatment f...
Read More...
Sep 19, 2022
Adial’s Micro-formulation: Opening New Massive Alcohol Use Disorder Treatment Market Opportunities
Key Highlights Through the use of genetic screening, i.e., a companion genetic bio-marker intended to identify patients most likely to respond to therapy, AD04 humanizes the alcohol use disorder treatment, which could lead to an increase in the usage of AD04Without the need for abstinence, AD04’s novel mechanism...
Read More...
Sep 16, 2022
Focal Segmental Glomerulosclerosis Market: Unfolding Insights into the Future
Currently, there are no FDA-approved therapies for FSGS. However, the therapeutic focal segmental glomerulosclerosis market in the seven major geographies mainly comprises off-label focal segmental glomerulosclerosis treatment options. The off-label therapies majorly include nonimmune therapies in conjunction wi...
Read More...
Sep 15, 2022
Aerin Medical’s RhinAer Stylus; CE Mark for Haemonetics’s VASCADE Vascular Closure Device; J&J Vision Launches ACUVUE OASYS MAX 1-Day; Olympus Launches VISERA ELITE III Surgical Visualization Platform; GlucoRx’s Non-Invasive Glucose Monitoring Platform; Medtronic-BioIntelliSense’s Partnership; Corindus’s CorPath GRX Neurovascular System Trial; GE & Lantheus [18F]flurpiridaz PET Radiotracer Trial; Pulmonx’s AeriSeal System Trial; AtriAN’s Second Study on Cardioneuroablation
Johnson & Johnson Vision Launches New Contact Lens Innovation ACUVUE® OASYS MAX 1-Day for Meeting the Needs of Digitally Intense Lifestyles On September 12, 2022, Johnson & Johnson Vision, a part of Johnson & Johnson and a global leader in the eyecare market, had announced the launch of its newest in...
Read More...
Aug 28, 2025
Navigating the Most Use Cases of Robotic Process Automation (RPA) in Healthcare
Robotic Process Automation (RPA) in healthcare involves utilizing software bots to automate routine and repetitive tasks, such as data entry, billing, scheduling, and claims processing. These bots mimic human actions on digital systems, aiming to enhance efficiency, minimize manual errors, and enable healthcare wor...
Read More...
Sep 13, 2022
Amgen Announced the Result of its CodeBreak-200 Trial; FDA Clears Bristol-Myers Squibb’s Deucravacitinib; BioNTech’s Amplified CAR-T Therapy; TIL Therapy Improves on Yervoy in Melanoma; GSK’s Daprodustat will have to face FDA Advisory Committee; Breakthrough Therapy Status to Pfizer’s Group B Strep Vaccine; EU Approves Gilead’ Tecartus; Gilead’ Trodelvy Results in TROPiCs-02 Trial
Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...
Read More...